Tilray Brands, Inc. - Common Stock (TLRY)

Tilray stock plunged yesterday, July 29, following a brutal fiscal Q4 earnings report that reinforced concerns about Tilray’s strategic direction and financial health spooking investors. Other LPs dropped in sympathy.

Tilray overpaid for acquisitions in 2021 -- and Tilray stock is paying for that mistake today.

Shares of Tilray are trading lower Tuesday morning. The company reported Q4 revenue that fell short of analyst expectations.

Cannabis company Tilray Brands (NASDAQ:TLRY) missed Wall Street’s revenue expectations in Q2 CY2025, with sales falling 2.3% year on year to $224.5 million. Its GAAP loss of $1.30 per share was significantly below analysts’ consensus estimates.

Tilray announces fiscal fourth-quarter revenue of $224.53 million, missing analyst estimates of $250.41 million, according to Benzinga Pro.

Cannabis company Tilray Brands (NASDAQ:TLRY) will be announcing earnings results this Monday afternoon. Here’s what you need to know.

Tilray's 15% stock price bump today makes zero sense.

What a brutal six months it’s been for Tilray. The stock has dropped 45.6% and now trades at $0.64, rattling many shareholders. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.

The NASDAQ and S&P 500 hit all-time highs on better-than-expected economic data; the market is confirming expectations for a strong second half

Shares of cannabis company Tilray Brands (NASDAQ:TLRY) jumped 3.3% in the afternoon session after President Trump signed a bill that could ease federal research restrictions on cannabis and psychedelics. 

Shares of cannabis company Tilray Brands (NASDAQ:TLRY) jumped 3.5% in the morning session on continued momentum that saw the stock rise significantly in July. 

U.S. stocks traded mostly flat on Monday as investors reacted to President Donald Trump's announcement of a 30% tariff on all imports from the EU and Mexico.

Tilray's recent 55% rally may draw investor attention, but do the potential benefits outweigh the continued risks of this cannabis leader?

Shares of cannabis company Tilray Brands (NASDAQ:TLRY) jumped 7.8% in the morning session after the U.S. Senate was scheduled to vote on the confirmation of a new Drug Enforcement Administration (DEA) chief, a crucial step for advancing cannabis rescheduling. 

Shares of Tilray Brands are trading higher Monday morning. The stock is building on a recent rally fueled by heavy trading volume and company announcements.

Shares of cannabis company Tilray Brands (NASDAQ:TLRY) jumped 17.8% in the afternoon session after the stock rallied on growing optimism regarding federal marijuana reform. The move comes as investors anticipate the potential reclassification of cannabis from a Schedule I to a Schedule III substance under federal law. Such a change would be a significant catalyst for the industry, as it would acknowledge the medical use of cannabis and could ease the severe tax burdens currently imposed on cannabis companies.